ImmunityBio, Inc. IBRX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total liabilities?
- ImmunityBio, Inc. (IBRX) reported total liabilities of $1.52B in Q1 2026.
- How has ImmunityBio, Inc.'s total liabilities changed year-over-year?
- ImmunityBio, Inc.'s total liabilities increased by 69.5% year-over-year, from $894.24M to $1.52B.
- What is the long-term trend for ImmunityBio, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total liabilities has grown at a 24.1% compound annual growth rate (CAGR), from $339.87M to $1B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.